ANDA 209677, held by Sola Pharms. Teriflunomide.
As of Nov 16, 2026, ANDA 209677 (Teriflunomide), held by Sola Pharms, was first approved by FDA on Sep 28, 2023, with 2 approved supplements and 0 published complete response letters.
| Sep 28, 2023 | Original application | Approved | |
| Jun 17, 2020 | Original application | Approved | None posted |
| Teriflunomide14MG · tablet;oral | Teriflunomide | Rx |
| Teriflunomide7MG · tablet;oral | Teriflunomide | Rx |
| Mar 7, 2025 | Supplement 2Labeling · Standard review | Approved | None posted |
| Mar 7, 2025 | Supplement 3Labeling · Standard review | Approved | None posted |
| Sep 28, 2023 | Original application | Approved | |
| Jun 17, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters